Global Parkinson's Disease Market 2014-2018

世界のパーキンソン病治療市場(2014-2018)

◆タイトル:Global Parkinson's Disease Market 2014-2018
◆商品コード:IRTNTR3862
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年7月23日
◆ページ数:97
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥308,000見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"世界のパーキンソン病治療市場(2014-2018)"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Parkinson’s Disease
Parkinson’s disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson’s disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported. Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson’s disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson’s disease patients under certain circumstances.

TechNavio’s analysts forecast the Global Parkinson’s Disease market will grow at a CAGR of 3.32 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Parkinson’s Disease market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to provide symptomatic relief in Parkinson’s disease.
The report also presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the Global Parkinson’s Disease market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio’s report, the Global Parkinson’s Disease Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Parkinson’s Disease market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• Boehringer Ingelheim GmbH
• GlaxoSmithKline plc
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
Other Prominent Vendors
• Abbvie Inc.
• Akorn Inc.
• Astellas Pharma Inc.
• Desitin Arzneimittel GmbH
• Endo International plc
• F. Hoffmann-La Roche Ltd.
• H. Lundbeck A/S
• Kyowa Hakko Kirin
• Merck & Co. Inc.
• Orion Corp.
• STADA Arzneimittel AG
• UCB Inc.
• US WorldMeds LLC
• Valeant Pharmaceuticals International Inc.
Key Market Driver
• Increase in Patient Population
• For a full, detailed list, view our report.
Key Market Challenge
• Generic Erosion
• For a full, detailed list, view our report.
Key Market Trend
• Reformulation of Marketed Drugs
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by MOA
07.1.1 Anticholinergics
07.1.2 Beta-Adrenergic Antagonists
07.1.3 COMT Inhibitors
07.1.4 Dopamine Agonists
07.1.5 Dopamine Replenishers
07.1.6 MAOB Inhibitors
07.1.7 Others
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Mergers and Acquisitions
16.2 Market Share Analysis 2013
16.2.1 Novartis
16.2.2 Boehringer
16.2.3 Teva
16.2.4 GlaxoSmithKline
17. Key Late-Stage Pipeline Candidates
17.1 Key Information for Late-Stage Pipeline Candidates
17.1.1 ABT-SLV187
17.1.2 BIA 9-1067
17.1.3 IPX066
17.1.4 KW-6002
17.1.5 NW 1015
17.1.6 OS-320
17.1.7 P2B 001
17.2 Key Late-Stage Discontinued Drug Candidates
18. Other Prominent Vendors
19. Key Vendor Analysis
19.1 Boehringer Ingelheim
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Revenue Segmentation by Business /Products
19.1.6 Sales by Geographical Segmentation
19.1.7 Key Information
19.1.8 SWOT Analysis
19.1.9 Strengths
19.1.10 Weaknesses
19.1.11 Opportunities
19.1.12 Threats
19.2 GlaxoSmithKline
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Sales by Geography
19.2.6 Pipeline Products
19.2.7 Business Strategy
19.2.8 Key Information
19.2.9 SWOT Analysis
19.2.10 Strengths
19.2.11 Weaknesses
19.2.12 Opportunities
19.2.13 Threats
19.3 Novartis
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation by Revenue 2013
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Sales by Geography
19.3.6 Business Strategy
19.3.7 Key Developments
19.3.8 SWOT Analysis
19.3.9 Strengths
19.3.10 Weaknesses
19.3.11 Opportunities
19.3.12 Threats
19.4 Teva
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation
19.4.4 Business Segmentation by Revenue 2013
19.4.5 Business Segmentation by Revenue 2012 and 2013
19.4.6 Sales by Geography
19.4.7 Business Strategy
19.4.8 Key Developments
19.4.9 SWOT Analysis
19.4.10 Strengths
19.4.11 Weakness
19.4.12 Opportunities
19.4.13 Threats
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Parkinson’s Disease Market 2013-2018 (US$ billion)
Exhibit 3: Global Parkinson’s Disease Market Segmentation by MOA
Exhibit 4: Anticholinergics Approved for the Treatment of Parkinson’s Disease
Exhibit 5: Beta-Adrenergic Antagonists Approved for the Treatment of Parkinson’s Disease
Exhibit 6: COMT Inhibitors Approved for the Treatment of Parkinson’s Disease
Exhibit 7: Dopamine Agonists Approved for the Treatment of Parkinson’s Disease
Exhibit 8: Dopamine Replenishers Approved for the Treatment of Parkinson’s Disease
Exhibit 9: MAOB Inhibitors Approved for the Treatment of Parkinson’s Disease
Exhibit 10: Some Other Drugs Approved for the Treatment of Parkinson’s Disease
Exhibit 11: Global Parkinson’s Disease Market by Geographical Segmentation 2013
Exhibit 12: Geography-wise Segmentation of Novartis’ Comtan and Stalevo Sales 2013
Exhibit 13: Geography-wise Segmentation of Exelon’s Sales in 2013
Exhibit 14: Geography-wise Revenue of Requip in 2013 (US$ million)
Exhibit 15: Business Segmentation of Boehringer Ingelheim Gmbh
Exhibit 16: Net Sales by Business of Boehringer Ingelheim GmbH
Exhibit 17: Revenue Segmentation by Business /Products (2013)
Exhibit 18: Sales by Geographical Segmentation (2013)
Exhibit 19: GlaxoSmithKline Plc: Business Segmentation 2013
Exhibit 20: GlaxoSmithKline Plc: Business Segmentation by Revenue 2012 and 2013 (in US$ billion)
Exhibit 21: GlaxoSmithKline Plc: Sales by Geography 2013
Exhibit 22: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 23: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 24: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 25: Novartis AG: Sales by Geography 2013
Exhibit 26: Teva Pharmaceutical Industries Ltd.: Business Segmentation
Exhibit 27: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2013
Exhibit 28: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 29: Teva Pharmaceutical Industries Ltd.: Sales by Geography 2013



【掲載企業】

Boehringer Ingelheim GmbH,GlaxoSmithKline plc,Novartis AG ,Teva Pharmaceutical Industries Ltd.,Abbvie Inc.
,Akorn Inc.,Astellas Pharma Inc.,Desitin Arzneimittel GmbH,Endo International plc,F. Hoffmann-La Roche Ltd.,H. Lundbeck A/S,Kyowa Hakko Kirin,Merck & Co. Inc.,Orion Corp.,STADA Arzneimittel AG,UCB Inc.,US WorldMeds LLC,Valeant Pharmaceuticals International Inc.


【資料のキーワード】

パーキンソン病、治療、薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[世界のパーキンソン病治療市場(2014-2018)] (Global Parkinson's Disease Market 2014-2018 / IRTNTR3862)販売に関する免責事項
[世界のパーキンソン病治療市場(2014-2018)] (Global Parkinson's Disease Market 2014-2018 / IRTNTR3862)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆